
According to a report by Medimagazin, Dr. Demet Can, Vice President of the Turkish National Allergy and Clinical Immunology Society, emphasized that e-cigarettes, whose age restrictions have been gradually lowered, pose a threat to teenagers as they double the risk of asthma and may worsen existing asthma conditions.
Professor Dmitry Zhan points out that e-cigarettes are electronic devices that rely on power sources to produce tobacco aerosols without burning tobacco. These devices include sensors, batteries, nicotine reservoirs, heating elements, glass fiber chips containing nicotine solutions, and reservoirs. Due to their convenience, e-cigarette use has significantly increased globally in recent years. He also states that the usage rate of e-cigarettes among adults is 6.5% in Spain and 8.5% in the United States.
Despite being marketed as less harmful than traditional tobacco, Professor Demet Jan states that e-cigarettes are often used as aids for quitting smoking or as smokeless tobacco alternatives. Recent research indicates that e-cigarette aerosol contains toxic substances such as tobacco-specific nitrosamines, formaldehyde, and acetaldehyde.
Professor Demet Jan pointed out that inhaling nicotine solution in e-cigarettes can cause an increase in inflammatory cells in the airways, including eosinophils, which worsens asthma symptoms. This has been proven in animal experiments. At the same time, when inhaling e-cigarette vapor, it is possible to inhale glass fiber particles and nicotine, which may eventually result in exposure to glass fiber particles in the respiratory system. He also discovered that this process, combined with smoking, can lead to the production of toxic reactive oxygen species and SOD (an enzyme) by glass fiber particles, triggering asthma.
Lastly, Professor Demet Jan stated, "In a recent study, it was found that nanoparticles of tin, chromium, and nickel in e-cigarette vapor cause inflammatory reactions in the respiratory tract and lungs, potentially playing a significant role in the onset of asthma.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com